Cite
HARVARD Citation
Choi, J. et al. (n.d.). Incidence of Benign and Malignant Neoplasms in Crohn's Disease Patients Aged ≤30 Years Versus 30‐64 Years Treated With Certolizumab Pegol: Results From a Pooled Safety Analysis of 15 Studies. American journal of gastroenterology. p. . [Online].